On Nov 2, 2021 Cambridge Epigenetix closed a Series D round and raised $88,000,000 from Ahren Innovation Capital, GV, New Science Ventures, Sequoia Capital, Temasek Holdings, Third Point, featuring lead investors Temasek Holdings.

About the company: Cambridge Epigenetix is located at United Kingdom, Europe.
“Cambridge Epigenetix is pioneering the development and application of novel epigenetics-based diagnostics and therapeutics that will revolutionise the way we detect and treat disease.”

Company website: http://www.cambridge-epigenetix.com